MONROVIA, Calif. — Cell Care Therapeutics, Inc., a biotechnology company whose mission is to advance stem-cell derived therapies in ophthalmology, today announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy (DR) and neovascular age-related macular degeneration (wet AMD), two of the leading causes of vision loss and blindness in the developed world. [Read more…]
TheraKine Provides Sustained Release Technology to Cell Care Therapeutics for Stem Cell Treatments of the Eye
Since the start of 2016, there has been a lot of licensing activity surrounding stem cell technologies, with key agreements linked between the Coriell Institute for Medical Research and Drs. Jeanne Loring and Franz Josef Muller (access to a bioinformatics assay that can assess the pluripotency of human induced pluripotent stem cells), Avapecia Life Sciences Corporation and Oceans Five-O Development Corporation (use of a cell insolation and enrichment technology to identify stem cell candidates for cell therapy applications), and most recently, TheraKine and Cell Care Therapeutics (use of injectable sustained release technology within stem cell therapies for eye disease). [Read more…]